source
- Belgian startup Armed Cell Therapeutics acquires Galapagos-derived CAR-T assets for €8 million upfrontArmed Cell Therapeutics, a new Belgian biotech chaired by former Galapagos CEO Paul Stoffels, has taken ownership of several cell therapy programs previously held by Lakefront Biotherapeutics. The…
- FDA unveils new rare disease framework to streamline evidence standards and speed therapiesThe FDA announced a new Rare Disease Framework Initiative aimed at standardizing how scientific evidence is evaluated for rare disease therapies. The framework seeks to apply consistent clinical t…